Table 1.
Characteristics of the included studies
| Author | Year | Country | Duration | Sample Size | Cancer type | Median age | Clinical parameters | Therapy administered | Cutoff value (NLR/PLR) |
Median follow‐up (months) |
Clinical factor |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Suh et al.31 | 2017 | Korea | 2013–2016 | 54 | NSCLC | 68 (43–80) | 1,3,4,5,6,7,8,9,10 | Nivo, Pemb | 5/169 | 26.2 (6.8–36.2) | OS, PFS |
| Bagley et al.14 | 2017 | USA | 2015–2016 | 175 | NSCLC | 68 (33–88) | 1,2,3,5,6,7,9,10 | Nivo | 5 | NR | OS, PFS |
| Shiroyama et al.15 | 2017 | Japan | 2015–2016 | 201 | NSCLC | 68 (27–87) | 1,3,5,10 | Nivo | 4 | 12.4 | PFS |
| Diem et al.16 | 2017 | Switzerland | 2015–2016 | 52 | NSCLC | 66 (46–88) | 1,3,5,7,8,9,10 | Nivo | 5/262 | 0–14 | OS, PFS |
| Sun et al.17 | 2017 | France | 2011–2014 | 167 | Multiple | 55 (20–82) | 1,3,8,10 | PD‐1, PD‐L1 | 4 | 12.9 (1.2–47.2) | OS |
| Cassidy et al.18 | 2017 | USA | 2006–2011 | 197 | Melanoma | 63 (10–91) | 1,3,4,5 | Ipi | 5 | 54.3 (5109) | OS, PFS |
| Ferrucci et al.19 | 2015 | Italy | 2010–2013 | 69(tr) | Melanoma | 62 (33–87) | 1,3,4,5,6,7,10 | Ipi | 5 | 10.6 | OS, PFS |
| 115(va1) | Melanoma | 63 | 1,3,5,10 | Ipi | 5 | 16.4 | OS | ||||
| 72(va2) | Melanoma | 62 | 1,3,5,10 | Ipi | 5 | 10.6 | OS | ||||
| 27(va3) | Melanoma | 55 (23–77) | 1,3,4,5 | Ipi | 5 | 9.6 | OS | ||||
| Jung et al.28 | 2017 | Korea | 2014–2015 | 104 | Melanoma | 58 (50–66) | 1,3,4,5,6,7,9 | Ipi | 5 | 7.1 (5.9–8.3) | OS, PFS |
| Khoja et al.20 | 2016 | Canada | 2008–2014 | 183 | Melanoma | 58 (24–89) | 1,3,4,6,9 | Ipi | 4/− | 7.5 (0.3,49.5) | OS, PFS |
| Zaragoza et al.21 | 2016 | France | 2015–2016 | 58 | Melanoma | 54.7 | 1,3,4,7 | Ipi | 4 | 31 | OS |
| Jeyakumar et al.22 | 2017 | USA | NR | 42 | mRCC | 42 (24–85) | 2,5 | Multiple | 3 | NR | OS, PFS |
| Fukui et al.23 | 2018 | Japan | 2016–2017 | 52 | NSCLC | 69 (46–83) | 1.3.4.5.6.7.9.10 | Nivo | 5 | 10.9 (5.6–16.4) | OS, PFS |
| Russo et al.24 | 2018 | Italy | NR | 28 | NSCLC | 68 (45–82) | 1.5.9.10 | Nivo | −/160 | NR | OS, PFS |
| Rosner et al.25 | 2018 | USA | NR | 209 | Melanoma | 60.5 (22–86) | 1.4.10 | Nivo, Ipi | 4.73 | 13.1 | OS, ORR |
| Fujisawa et al.30 | 2018 | Japan | NR | 90 | Melanoma | NR | NR | Nivo | 2.2 | NR | OS |
| Bilen et al.26 | 2018 | USA | 2015–2016 | 38 | mRCC | 69 (28–80) | 1.2.3. | Nivo | 5.5 | NR | OS, PFS |
| Park et al.27 | 2018 | USA | 2015–2017 | 159 | NSCLC | 68 (41–91) | 1.2.3.4.9.10 | Nivo | 5 | NR | OS, PFS |
Ipi, ipilimumab; mRCC, metastatic renal cell carcinoma; Nivo, nivolumab; NR, not reported; NSCLC, non‐small cell lung cancer; OS, overall survival; PD‐1, anti‐PD‐1 antibody; PD‐L1, anti‐PD‐L1 antibody; Pemb, pembrolizumab; PFS, progression‐free survival; tr, training group; va, validation group; 1, gender; 2, race; 3, performance status; 4, stage; 5, histological subtype; 6, adverse effect; 7, metastatic disease; 8, PD‐L1expression; 9, driver mutation; 10, previous lines of treatment.